Loading
A phase 1/2 trial of TG4050 in head and neck squamous cell carcinoma, run by Transgene, active and no longer recruiting.
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer is a phase 1/2 interventional study registered as NCT04183166 by Transgene, with 80 participants enrolled, started 2019-12-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: TG4050.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/